agilon health (NYSE: AGL) CFO gets 600K restricted stock units

Rhea-AI Filing Summary

agilon health, inc. reported an insider equity award to its Chief Financial Officer, Jeffrey A. Schwaneke. On January 10, 2026, he received 600,000 shares of common stock in the form of restricted stock units at a stated price of $0 per share. These restricted stock units vest in three equal installments on each anniversary of January 10, 2026, providing a three-year vesting schedule. Following this grant, Schwaneke beneficially owns 1,675,122 shares of agilon health common stock, which includes restricted stock units, all held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schwaneke Jeffrey A.

(Last) (First) (Middle)

C/O AGILON HEALTH, INC.

440 POLARIS PARKWAY, SUITE 550

(Street)

WESTERVILLE OH 43082

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
agilon health, inc. [ AGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/10/2026		A		600,000(1)	A	$0	1,675,122(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units that vest in three equal installments on each anniversary of January 10, 2026.

2. Includes restricted stock units.

Remarks:

	/s/ Mimi Yang, as Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did agilon health (AGL) report for its CFO?

agilon health reported that Chief Financial Officer Jeffrey A. Schwaneke received an award of 600,000 shares of common stock in the form of restricted stock units on January 10, 2026.

At what price were the 600,000 agilon health (AGL) shares granted to the CFO?

The 600,000 restricted stock units tied to agilon health common stock were recorded at a price of $0 per share, reflecting a compensation grant rather than an open-market purchase.

How do the CFO’s restricted stock units in agilon health (AGL) vest?

The restricted stock units granted to the CFO vest in three equal installments on each anniversary of January 10, 2026, creating a three-year vesting period.

How many agilon health (AGL) shares does the CFO beneficially own after this Form 4 transaction?

After the reported award, Chief Financial Officer Jeffrey A. Schwaneke beneficially owns 1,675,122 shares of agilon health common stock, including restricted stock units, held directly.

Is the reported agilon health (AGL) transaction a purchase or a compensation grant?

The Form 4 shows a transaction coded "A" at $0 per share with a footnote describing restricted stock units, indicating this is an equity compensation grant, not a market purchase.